Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids

Abstract

A 75-year-old female with no history of lung disease developed severe pulmonary fibrosis within 1 month of acute severe COVID-19 pneumonia. She developed dry basal crackles, hypoxia needing home oxygen, and computed tomography changes which dramatically evolved from acute ground-glass opacities to honeycombing and traction bronchiectasis. Interestingly, these changes occurred despite her being on steroids through most of her hospital stay. She is being commenced on pirfenidone and her responses are carefully monitored, but the role of antifibrotic drugs are unclear and will only be established from large clinical trials.

Keywords

• antifibrotics
• covid-19 sequelae
• pulmonary fibrosis (interstitial lung disease)
• sars-co-v-2